Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13303931 | 0.88 | PIK3CD (0.42) | PIK3CDSLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL10081589 | 0.87 | PIK3CD (0.42) | PIK3CDSLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL16549293 | 0.84 | PIK3CD (0.64) | PIK3CDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3410639 | 0.80 | ALDH1A1 (0.42) | PIK3CDALDH1A1 | |
| SCHEMBL15308459 | 0.79 | PIK3CD (0.37) | PIK3CDSLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL13934508 | 0.79 | CA12 (0.52) | PIK3CDSLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL6960580 | 0.79 | PIK3CD (0.71) | PIK3CDALDH1A1 | |
| SCHEMBL14402195 | 0.79 | PIK3CD (0.58) | PIK3CDSLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL22510247 | 0.77 | SLC6A2 (0.39) | PIK3CDSLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL9972864 | 0.77 | MAPT (0.55) | PIK3CDSLC6A2SLC6A4SLC6A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | PIK3CD 2726/4885SLC6A2 4557/4885SLC6A4 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.